Indivior Pharmaceuticals (INDV) Receivables (2021 - 2026)

Indivior Pharmaceuticals' Receivables history runs 6 years deep, the most recent figure standing at $273.0 million for Q1 2026.

• On a quarterly basis, Receivables rose 12.35% year-over-year to $273.0 million in Q1 2026; TTM through Mar 2026 was $273.0 million, a 12.35% increase from a year earlier, with the FY2025 full-year figure at $255.0 million, changed 0.39% from the prior year.
• Receivables climbed to $273.0 million in Q1 2026 per INDV's latest filing, from $255.0 million in the prior quarter.
• Across five years, Receivables topped out at $273.0 million in Q1 2026 and bottomed at $220.0 million in Q4 2022.
• The 5-year median for Receivables is $255.0 million (2023), against an average of $250.1 million.
• Across the five-year window, Receivables gained 15.91% in 2023 and dropped 0.39% in 2025, its largest moves.
• Year by year, Receivables stood at $220.0 million in 2022, then increased by 15.91% to $255.0 million in 2023, then advanced by 0.39% to $256.0 million in 2024, then fell by 0.39% to $255.0 million in 2025, then rose by 7.06% to $273.0 million in 2026.
• Per Business Quant, the three latest INDV Receivables figures stand at $273.0 million (Q1 2026), $255.0 million (Q4 2025), and $259.0 million (Q3 2025).